孤独症谱系障碍临床辅助药物应用进展
Progress in the Application of Clinical Adjuvant Drugs in Autism Spectrum Disorder
DOI: 10.12677/ijpn.2026.154017, PDF,    科研立项经费支持
作者: 尹晓莉, 蒲昭霞, 徐 磊*, 易 媛：成都西南康复医院发育行为科，四川 成都
关键词: 孤独症谱系障碍；共病；药物；辅助治疗；Autism Spectrum Disorder； Comorbidity； Drugs； Adjuvant Therapy
摘要: 孤独症谱系障碍(ASD)是一种复杂神经发育障碍，临床表现为社会交往、交流障碍和重复刻板行为、兴趣狭窄。目前孤独症谱系障碍暂无特效药物，其康复和预后仍以教育训练为主。然而，孤独症谱系障碍儿童除了核心症状外，在成长过程中也常会伴随注意力障碍、情绪障碍或睡眠障碍等问题，这些伴随的问题严重影响其成长发育和康复训练。因此，临床中也常采用一些药物来辅助治疗相关伴随问题。本文介绍临床中常用的辅助治疗药物，包括SSRIs类、注意缺陷多动障碍类、情绪稳定剂和AAPs药物在临床中的应用，为孤独症谱系障碍的临床管理提供参考。
Abstract: Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder with clinical manifestations of social interaction, communication disorder, repetitive stereotyped behavior and narrow interest. At present, there is no specific drug for autism spectrum disorder, and its rehabilitation and prognosis are still mainly based on education and training. However, in addition to the core symptoms, children with autism spectrum disorder often have problems such as attention disorder, emotional disorder or sleep disorder during their growth, which seriously affect their growth and development and rehabilitation training. Therefore, some drugs are often used in clinic to assist in the treatment of associated problems. This article introduces the clinical application of commonly used adjuvant drugs, including SSRIs, attention deficit hyperactivity disorder, mood stabilizers and AAPS drugs, so as to provide reference for the clinical management of autism spectrum disorder.
文章引用：尹晓莉, 蒲昭霞, 徐磊, 易媛. 孤独症谱系障碍临床辅助药物应用进展[J]. 国际神经精神科学杂志, 2026, 15(4): 155-159. https://doi.org/10.12677/ijpn.2026.154017

参考文献

[1] 中华医学会儿科学分会发育行为学组, 中国医师协会儿科分会儿童保健学组. 中国低龄儿童孤独症谱系障碍早期诊断专家共识[J]. 中华儿科杂志, 2022, 60(7): 640-646.
[2] Maenner, M.J., et al. (2023) Prevalence and Characteristics of Autism Spectrum Disorder among Children Aged 8 Years—Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2020. MMWR Surveillance Summaries, 72, 1-14.
https://doi.org/10.15585/mmwr.ss7202a1
[3] 赵亚楠, 李智文, 李琳, 等. 中国0~6岁儿童孤独症谱系障碍筛查患病现状[J]. 中国生育健康杂志, 2023, 34(5): 423-428.
[4] Al-Dakroury, W.A., Alnemary, F.M. and Alnemary, F. (2022) Autism in the Kingdom of Saudi Arabia: Current Situation and Future Perspectives for Services and Research. Perspectives of the ASHA Special Interest Groups, 7, 2104-2109.
https://doi.org/10.1044/2022_persp-22-00087
[5] Buescher, A.V.S., Cidav, Z., Knapp, M. and Mandell, D.S. (2014) Costs of Autism Spectrum Disorders in the United Kingdom and the United States. JAMA Pediatrics, 168, 721-728.
https://doi.org/10.1001/jamapediatrics.2014.210
[6] Aljead, M., Qashta, A., Jalal, Z. and Jones, A.M. (2025) Review of Autism Spectrum Disorder (ASD): Epidemiology, Aetiology, Pathology, and Pharmacological Treatment. Pharmaceuticals, 18, Article No. 1644.
https://doi.org/10.3390/ph18111644
[7] Rezaei, M., Moradi, A., Tehrani-Doost, M., Hassanabadi, H. and Khosroabadi, R. (2018) Effects of Combining Medication and Pivotal Response Treatment on Aberrant Behavior in Children with Autism Spectrum Disorder. Children, 5, Article No. 19.
https://doi.org/10.3390/children5020019
[8] Alsayouf, H.A., Talo, H. and Biddappa, M.L. (2022) Core Signs and Symptoms in Children with Autism Spectrum Disorder Improved after Starting Risperidone and Aripiprazole in Combination with Standard Supportive Therapies: A Large, Single-Center, Retrospective Case Series. Brain Sciences, 12, Article No. 618.
https://doi.org/10.3390/brainsci12050618
[9] Manter, M.A., Birtwell, K.B., Bath, J., Friedman, N.D.B., Keary, C.J., Neumeyer, A.M., et al. (2025) Pharmacological Treatment in Autism: A Proposal for Guidelines on Common Co-Occurring Psychiatric Symptoms. BMC Medicine, 23, Article No. 11.
https://doi.org/10.1186/s12916-024-03814-0
[10] Aishworiya, R., Valica, T., Hagerman, R. and Restrepo, B. (2024) An Update on Psychopharmacological Treatment of Autism Spectrum Disorder. Focus, 22, 198-211.
https://doi.org/10.1176/appi.focus.24022006
[11] Simonoff, E., Mowlem, F., Pearson, O., Anagnostou, E., Donnelly, C., Hollander, E., et al. (2022) Citalopram Did Not Significantly Improve Anxiety in Children with Autism Spectrum Disorder Undergoing Treatment for Core Symptoms: Secondary Analysis of a Trial to Reduce Repetitive Behaviors. Journal of Child and Adolescent Psychopharmacology, 32, 233-241.
https://doi.org/10.1089/cap.2021.0137
[12] Davico, C., Secci, I., Vendrametto, V., et al. (2023) Pharmacological Treatments in Autism Spectrum Disorder: A Narrative Review. Journal of Psychopathology, 29, 38-52.
[13] Sugaya, L.S., Farhat, L.C., Califano, P. and Polanczyk, G.V. (2023) Efficacy of Stimulants for Preschool Attention‐Deficit/Hyperactivity Disorder: A Systematic Review and Meta‐Analysis. JCPP Advances, 3, e12146.
https://doi.org/10.1002/jcv2.12146
[14] Cortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, A.J., Carucci, S., et al. (2018) Comparative Efficacy and Tolerability of Medications for Attention-Deficit Hyperactivity Disorder in Children, Adolescents, and Adults: A Systematic Review and Network Meta-Analysis. The Lancet Psychiatry, 5, 727-738.
https://doi.org/10.1016/s2215-0366(18)30269-4
[15] Zhang, Y., Yin, L., You, C., Liu, C., Dong, P., Xu, X., et al. (2023) Efficacy and Safety of Methylphenidate and Atomoxetine in Medication-Naive Children with Attention-Deficit Hyperactivity Disorder in a Real-World Setting. Drugs in R&D, 24, 29-39.
https://doi.org/10.1007/s40268-023-00445-3
[16] Hellings, J. (2023) Pharmacotherapy in Autism Spectrum Disorders, Including Promising Older Drugs Warranting Trials. World Journal of Psychiatry, 13, 262-277.
https://doi.org/10.5498/wjp.v13.i6.262
[17] Wasserman, S., Iyengar, R., Chaplin, W.F., Watner, D., Waldoks, S.E., Anagnostou, E., et al. (2006) Levetiracetam versus Placebo in Childhood and Adolescent Autism: A Double-Blind Placebo-Controlled Study. International Clinical Psychopharmacology, 21, 363-367.
https://doi.org/10.1097/01.yic.0000224787.13782.0f
[18] Rugino, T.A. and Samsock, T.C. (2002) Levetiracetam in Autistic Children: An Open-Label Study. Journal of Developmental & Behavioral Pediatrics, 23, 225-230.
https://doi.org/10.1097/00004703-200208000-00006
[19] Leucht, S., Priller, J. and Davis, J.M. (2024) Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application. American Journal of Psychiatry, 181, 865-878.
https://doi.org/10.1176/appi.ajp.20240738
[20] Zhou, M.S., Nasir, M., Farhat, L.C., Kook, M., Artukoglu, B.B. and Bloch, M.H. (2021) Meta-Analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders. Journal of the American Academy of Child & Adolescent Psychiatry, 60, 35-45.
https://doi.org/10.1016/j.jaac.2020.03.007
[21] Meza, N., Franco, J.V., Sguassero, Y., Núñez, V., Escobar Liquitay, C.M., Rees, R., et al. (2025) Atypical Antipsychotics for Autism Spectrum Disorder: A Network Meta-Analysis. Cochrane Database of Systematic Reviews, 2025, CD014965.
https://doi.org/10.1002/14651858.cd014965.pub2
[22] Pringsheim, T., Panagiotopoulos, C., Davidson, J. and Ho, J. (2011) Evidence-Based Recommendations for Monitoring Safety of Second-Generation Antipsychotics in Children and Youth. Paediatrics & Child Health, 16, 581-589.
https://doi.org/10.1093/pch/16.9.581
[23] Yanisa, W., Ejdrup, S.A., et al. (2022) CYP2D6 Genetic Variation and Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis. Frontiers in Psychology, 12, Article ID: 768748.
[24] Lopes, L.P.N., Itria, A. and Lopes, L.C. (2023) Budget Impact Analysis of Risperidone Use and Adverse Event Monitoring in Autism Spectrum Disorder in Brazil: Assessment of Theoretical versus Real Data. PharmacoEconomics—Open, 7, 951-961.
https://doi.org/10.1007/s41669-023-00436-9